Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for shares of Recursion Pharmaceuticals in a report issued on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.29) for the quarter, down from their prior estimate of ($0.27). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.35) EPS.
A number of other brokerages have also weighed in on RXRX. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target for the company. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.00.
Get Our Latest Analysis on RXRX
Recursion Pharmaceuticals Trading Up 5.8%
Shares of NASDAQ RXRX opened at $5.84 on Monday. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $4.92 and a two-hundred day simple moving average of $6.00. The firm has a market cap of $2.37 billion, a PE ratio of -3.30 and a beta of 0.91. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm earned ($0.39) earnings per share.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. ARK Investment Management LLC grew its stake in Recursion Pharmaceuticals by 7.6% during the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock worth $184,174,000 after buying an additional 2,469,104 shares during the last quarter. Vanguard Group Inc. grew its stake in Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock worth $229,908,000 after buying an additional 9,737,196 shares during the last quarter. Softbank Group CORP. purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth $99,152,000. Kinnevik AB publ grew its stake in Recursion Pharmaceuticals by 12.8% during the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company’s stock worth $71,067,000 after buying an additional 1,528,503 shares during the last quarter. Finally, Novo Holdings A S purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth $68,375,000. 89.06% of the stock is owned by institutional investors.
About Recursion Pharmaceuticals
(Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Receive News & Ratings for Recursion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
